- Market Intelligence
- Enterprise Platform
- News Data Feeds API
- Executive Briefings
- About Us
- Contact Us
- Case Studies
- Data Sheets
GlaxoSmithKline (LON:GSK) released its quarterly earnings data on Wednesday, July 25th. The company reported GBX 52.70 ($0.67) EPS for the quarter, Bloomberg Earnings reports. GlaxoSmithKline had a net margin of 9.36% and a return on equity of 348.10%.
Merck & Co., Inc. (NYSE:MRK) issued an update on its FY18 earnings guidance on Friday morning. The company provided EPS guidance of $4.22-4.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.24.
Saif currently works as a content writer for CMFE Research, AlgosOnline and a couple of other platforms. A Computer Science graduate who has a zest for writing over coding, commenced his journey in the writing industry as a freelancer.
Celgene (NASDAQ:CELG) posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.16 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.05, Bloomberg Earnings reports. Celgene had a return on equity of 87.28% and a net margin of 19.81%.
AstraZeneca plc (LON:AZN) declared a dividend on Thursday, July 26th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, August 9th will be paid a dividend of GBX 68.40 ($0.87) per share by the biopharmaceutical company on Monday, September 10th.
Equities research analysts expect that Bristol-Myers Squibb Co (NYSE:BMY) will post sales of $5.65 billion for the current quarter, according to Zacks. Four analysts have issued estimates for Bristol-Myers Squibb’s earnings, with the highest sales estimate coming in at $5.71 billion and the lowest estimate coming in at $5.58 billion.
Sligo is to suffer the loss of 165 jobs in the next three years as GlaxoSmithKline closes its manufacturing plant there. The company told employees at Stiefel Laboratories of its proposal to phase down production at the skincare manufacturing site.
Gilead Sciences (NASDAQ:GILD) issued its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.56 by $0.35, Bloomberg Earnings reports. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%.
Saturday August 18, 2018 11:19 AM Bayer acquired Monsanto Co. for $66 billion in June. Bayer vowed to step up its defense against a wave of U.S. lawsuits over the herbicide Roundup as it began the formal integration of Monsanto Co., acquired for $66 billion in June.
Zoetis (NYSE:ZTS) announced its earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.06, Bloomberg Earnings reports. Zoetis had a return on equity of 72.30% and a net margin of 19.95%.
Merck issued the following announcement on Aug. 17. Healthy Interactions, a global leader in health education, in collaboration with Merck (NYSE : MRK ), known as MSD outside the United States and Canada, announced the launch of map4health™ – a digital platform and mobile application in the U.S.
Alexion Pharmaceuticals (NASDAQ:ALXN) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share guidance of $7.00-7.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.02.
Bayer Rejects Media Report of Fresh Dicamba Lawsuits MADRID – Bayer AG on Friday rejected a report by German magazine WirtschaftsWoche, which claimed that farmers in the US had filed class-action lawsuits related to the Monsanto-produced Dicamba herbicide.
Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins Novo Nordisk gains full rights to Ziylo's early-stage glucose binding molecules in a staged acquisition with a potential deal value that could
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts.
PARSIPPANY, N.J. and UNION CITY, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Abaxis, Inc. (NASDAQ:ABAX) today announced a definitive merger agreement pursuant to which Zoetis will acquire Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate.
BERLIN, Aug. 16 (Xinhua) — German multinational pharmaceutical and life sciences company Bayer AG officially completed its acquisition of Monsanto on Thursday by fulfilling all requirements set by antitrust regulators in the 63-billion-euro (72-billion-U.S.-dollar) agrochemical industry merger.
I close with a brief discussion of a source of ideas for JNJ longs looking to exit. In light of the additional litigation risk, I present a couple of updated hedges for JNJ longs. I also discuss the implication of JNJ's low hedging costs.
→ David Hung offered a hard sell of his experimental PARP drug talazoparib while bidders lined up in what turned out as a $14 billion Medivation buyout by Pfizer. Now researchers are spelling out all the data in an article in the New England Journal of Medicine as Pfizer lines up a quick review and likely OK for a drug that will face some well entrenched competitors.
Aug 17 – Bristol-Myers Squibb Co said on Friday the U.S. Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.